Oxidative Stress for Chronic Pain

"Indeed, information found on clinicaltrials.gov reveals that this research study is actively seeking suitable participants. The trial was first listed on February 1st, 2024 and last revised on January 30th, 2024. It aims to recruit a total of 75 individuals from one designated site."

"Participants aged between 18 and 75 experiencing chronic pain are eligible for inclusion in this study, with a total enrollment cap of 75 individuals."

"Potential candidates for this research study must be above 18 years of age but under the age of 75."

"Indeed, as per clinicaltrials.gov, this research endeavor is currently in search of eligible participants. The trial was officially introduced on February 1st, 2024, with the most recent modification made on January 30th of the same year. A total of 75 individuals are sought after at a single designated site."

"Given that this is a Phase 2 trial, the safety rating for Nerve Health by our team at Power stands at 2. While there is some existing safety data, efficacy evidence is currently lacking."

"As per Ethos Research & Development, the primary focus of this investigation is to assess Quality-of-life metrics throughout 1 and 3 months following supplementation. Secondary evaluations will encompass Anxiety symptoms (defined as the proportion of participants experiencing a reduction in anxiety symptoms), Depression symptoms (expressed as the percentage of individuals manifesting decreased depression symptoms), and Visual Analog Scale pain scores which entail inquiries about current, worst, least, and average pain levels since the preceding visit. This scale employs a range from 0 ("no discomfort") to 10 ("most severe agony"), with higher values indicating poorer outcomes."